Stifel Nicolaus Lowers Nyxoah (NASDAQ:NYXH) Price Target to $10.00

Nyxoah (NASDAQ:NYXH) had its price target reduced by analysts at Stifel Nicolaus from $11.00 to $10.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective indicates a potential upside of 224.68% from the stock’s previous close.

Other equities research analysts also recently issued reports about the company. Cantor Fitzgerald upgraded Nyxoah to a “strong-buy” rating in a report on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nyxoah in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $11.33.

Nyxoah Trading Down 0.3%

NASDAQ NYXH opened at $3.08 on Friday. Nyxoah has a 12 month low of $3.02 and a 12 month high of $11.87. The company has a current ratio of 1.70, a quick ratio of 1.41 and a debt-to-equity ratio of 0.40. The stock’s fifty day moving average price is $4.33 and its 200-day moving average price is $4.83. The stock has a market cap of $104.90 million, a P/E ratio of -1.15 and a beta of 1.56.

Nyxoah (NASDAQ:NYXH) last announced its quarterly earnings results on Thursday, March 19th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.03). Nyxoah had a negative net margin of 884.69% and a negative return on equity of 128.85%. The firm had revenue of $6.62 million for the quarter, compared to the consensus estimate of $5.70 million. As a group, equities analysts forecast that Nyxoah will post -1.91 EPS for the current fiscal year.

Hedge Funds Weigh In On Nyxoah

A number of institutional investors and hedge funds have recently modified their holdings of NYXH. Franklin Resources Inc. increased its position in Nyxoah by 0.9% during the second quarter. Franklin Resources Inc. now owns 294,990 shares of the company’s stock valued at $2,207,000 after acquiring an additional 2,655 shares during the last quarter. Bank of America Corp DE boosted its position in Nyxoah by 72.4% in the second quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock worth $59,000 after purchasing an additional 3,303 shares during the last quarter. Raymond James Financial Inc. grew its stake in shares of Nyxoah by 35.6% during the 3rd quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock valued at $59,000 after purchasing an additional 3,353 shares during the period. Deutsche Bank AG grew its stake in shares of Nyxoah by 40.0% during the 4th quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after purchasing an additional 10,000 shares during the period. Finally, Rossmore Private Capital increased its position in shares of Nyxoah by 12.6% during the 3rd quarter. Rossmore Private Capital now owns 132,746 shares of the company’s stock valued at $616,000 after purchasing an additional 14,806 shares during the last quarter.

Key Headlines Impacting Nyxoah

Here are the key news stories impacting Nyxoah this week:

• Positive Sentiment: Company reports strong U.S. launch momentum: first full quarter of U.S. commercialization drove 347% YoY net revenue growth (Q4 net revenue €5.6M), 145 surgeons trained, 57 U.S. accounts activated, consistent reimbursement to date, and plans to expand manufacturing to support growth — bolstering medium-term commercial outlook. Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
• Positive Sentiment: Q4 revenue topped some estimates (reported ~€5.6M net / $6.62M reported in USD), reinforcing that commercial ramp is translating into sales and supporting the company’s stated 2026 growth trajectory. Nyxoah SA (NYXH) Q4 2025 Earnings Call Highlights: U.S. Launch Success and Financial Challenges
• Neutral Sentiment: Stifel lowered its price target from $11 to $10 but kept a Buy rating — this trims upside in models but maintains institutional confidence in the commercial story. Benzinga
• Neutral Sentiment: Shareholding disclosure: Robert Taub / Robelga SRL filed a transparency notification after Robelga SRL crossed above the 3% threshold; group ownership reportedly unchanged — a minor governance/ownership update. Publication relating to transparency notifications
• Negative Sentiment: Earnings miss and heavy losses: reported EPS around ($0.69) slightly missed consensus (~$0.65) and the company still shows very negative margins and ROE, underscoring ongoing cash consumption and near-term profitability risk. Nyxoah Q4 Earnings Report / Transcript
• Negative Sentiment: Analyst/media coverage highlights the loss and EPS miss, which can pressure valuation and keep volatility elevated until consistent profitability or clear guidance is provided. Zacks: Nyxoah SA Reports Q4 Loss, Misses Revenue Estimates

Nyxoah Company Profile

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.